177Lu-rhPSMA-10.1在177Lu-PSMA-I&T靶向放射配体治疗后的转移性去势抵抗性前列腺癌患者中诱导肿瘤缓解
本文报道一例86岁转移性去势抵抗性前列腺癌男性患者,接受177Lu-PSMA-I&T放射配体治疗初期部分缓解后,再行2个周期出现血清PSA升高,并与PSMA阳性程度增加及新发骨病灶相关;随后基于同情用药改为177Lu-rhPSMA-10.1治疗,获得再次肿瘤缓解。
要点
- 177Lu-rhPSMA-10.1是经药理学与药代动力学优化的新型PSMA靶向放射性药物。
- 患者在177Lu-PSMA-I&T治疗初期部分缓解后,再行2个周期出现PSA升高及新发骨病灶。
- 改为177Lu-rhPSMA-10.1同情用药后,患者获得再次肿瘤缓解。
核心结论
- 对于177Lu-PSMA-I&T治疗后出现PSA升高及新发骨病灶的转移性去势抵抗性前列腺癌患者,改为177Lu-rhPSMA-10.1同情用药后获得再次肿瘤缓解。
研究设计与样本
- 本文为单例病例报告,患者为86岁男性转移性去势抵抗性前列腺癌,接受177Lu-PSMA-I&T治疗后基于同情用药改为177Lu-rhPSMA-10.1治疗。
主要发现
- 患者接受177Lu-PSMA-I&T治疗初期获得部分缓解,再行2个周期后血清PSA水平升高,并与PSMA阳性程度增加及新发骨病灶相关。
- 改为177Lu-rhPSMA-10.1治疗后,患者获得再次肿瘤缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
177 Lu-rhPSMA-10.1 is a novel PSMA-targeting radiopharmaceutical that has been optimized in terms of pharmacological and pharmacokinetic properties and may be therefore advantageous in treatment of metastatic castrate-resistant prostate cancer. In this image, we present the case of an 86-year-old man with metastastic castrate-resistant prostate cancer undergoing 177 Lu-PSMA-I&T treatment. After initial partial response to radioligand therapy, another 2 treatment cycles resulted in a rising serum PSA level that could be correlated with increasingly PSMA-positive as well as a new bone lesion. Consequently, the patient was changed to 177 Lu-rhPSMA-10.1 treatment on a compassionate use basis achieving a renewed tumor response.
引用
- Bundschuh RA, Pfob CH, Wienand G, et al. 177 Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With 177 Lu-PSMA-I&T. Clin Nucl Med. 2023. PMID: 36692961. doi:10.1097/RLU.0000000000004573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。